The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies

Cancer Treatment Reviews
Madeleine Duvic, Meletios A Dimopoulos

Abstract

Histone acetyltransferases and histone deacetylases (HDACs) are multifunctional enzymes that posttranslationally modify both histone and nonhistone acetylation sites, affecting a broad range of cellular processes (e.g., cell cycle, apoptosis, and protein folding) often dysregulated in cancer. HDAC inhibitors are small molecules that directly interact with HDAC catalytic sites preventing the removal of acetyl groups, thereby counteracting the effects of HDACs. Since the first HDAC inhibitor, valproic acid, was investigated as a potential antitumor agent, there have been a number of other HDAC inhibitors developed to improve efficacy and safety. Despite significant progress in the management of patients with hematologic malignancies, overall survival is still poor. The discovery that HDACs may play a role in hematologic malignancies and preclinical studies showing promising activity with HDAC inhibitors in various tumor types, led to clinical evaluation of HDAC inhibitors as potential treatment options for patients with advanced hematologic malignancies. The Food and Drug Administration has approved two HDAC inhibitors, vorinostat (2006) and romidepsin (2009), for the treatment of cutaneous T-cell lymphoma. This review highlights...Continue Reading

References

Dec 7, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorWilliam K Kelly
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard L PiekarzSusan E Bates
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric H RubinMarian Iwamoto
Apr 18, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bhupinder S MannRichard Pazdur
May 15, 2007·Biochemical Pharmacology·Keith B Glaser
Jun 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Elise A OlsenMadeleine Duvic
Feb 26, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M CrumpB D Cheson
Feb 29, 2008·The Oncologist·Marshall A Lichtman
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Evanthia GalanisJan C Buckner
Apr 25, 2009·Seminars in Hematology·Constantine S MitsiadesPaul G Richardson
Jun 12, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L StimsonN B La Thangue
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ashraf BadrosSteven Grant
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard L PiekarzSusan E Bates
Nov 6, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pamela N MunsterMarian Iwamoto
Feb 4, 2010·International Journal of Cancer. Journal International Du Cancer·Wenlin ShaoPeter Atadja
Aug 5, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John J Wright
Mar 1, 2011·Blood·Richard L PiekarzSusan E Bates
Jan 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bertrand CoiffierSteven Horwitz
Oct 9, 2012·Clinical Lymphoma, Myeloma & Leukemia·Donna M WeberSundar Jagannath
Sep 11, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jesús F San-MiguelKenneth C Anderson

❮ Previous
Next ❯

Citations

Jun 12, 2016·Trends in Microbiology·Chiaho ShihRen-Shiang Jhou
Jan 22, 2017·Bioorganic & Medicinal Chemistry Letters·Nethrie D IdippilyBin Su
Jun 9, 2016·Journal of Medical Ethics·Daniel R Kuritzkes
Feb 2, 2017·Journal of Otolaryngology - Head & Neck Surgery = Le Journal D'oto-rhino-laryngologie Et De Chirurgie Cervico-faciale·Cameron LindsayVincent L Biron
Feb 20, 2018·Pharmacological Reports : PR·Paulina MisztakMagdalena Sowa-Kućma
Jul 25, 2018·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mario de la Fuente RevengaJavier González-Maeso
Sep 4, 2020·Journal of Gastrointestinal Cancer·Bondada Venkata Mani Anirudh, Devaraj Ezhilarasan
Jul 20, 2018·Nature Reviews. Immunology·Wilfried Ellmeier, Christian Seiser
Dec 2, 2020·Clinical Epigenetics·Krzysztof T JurdzińskiAleksander M Grabiec
Jul 2, 2020·Journal of Medicinal Chemistry·Terence C S HoA Ganesan
May 11, 2019·Experimental Cell Research·Daniel W ColeAndrew M Fribley
Oct 30, 2020·The Journal of Organic Chemistry·Chun-Hua HuangBen-Zhan Zhu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis